register

News & Trends - Pharmaceuticals

BioCurate and Takeda renew partnership ‘to create transformational therapies for patients’

Health Industry Hub | September 21, 2023 |

Pharma News: The pioneering collaboration between The University of Melbourne and Monash University, BioCurate, has officially renewed its partnership with the global pharmaceutical giant, Takeda. The strategic alliance is set to revolutionise the landscape of early-stage therapeutic research, promising significant advancements in medical treatment.

This partnership marks a significant milestone for both entities, exponentially enhancing their scientific and commercialisation capabilities. The collaboration will grant them increased access to potential projects in critical therapeutic areas, presenting an opportunity for co-investment and further research. This strategic move aims to bolster their ability to identify and push forward the most promising projects in their quest for therapeutic breakthroughs.

In the coming months, the two powerhouses will pool their expertise and resources to tackle challenges hindering the translation and commercialisation of selected projects. This united effort will provide invaluable advice and expertise, streamlining the development process and bringing us one step closer to life-changing therapies.

Dr Eric Hayes, Director of Partnerships at BioCurate, expressed his enthusiasm about the renewed alliance, stating, “We’re thrilled to renew our strategic alliance with Takeda, whose world-class team has a proven track record of successful collaborations to bring new, commercially viable medicines to market. We have some of the world’s best medical research teams operating out of Victoria’s laboratories; Takeda’s expertise will help ensure this research has the best possible chance of becoming therapies that improve people’s lives.”

Dr Michael Martin, Head of Takeda’s Centre for External Innovation, highlighted the significance of the collaboration. He said “Continuing our collaboration with BioCurate renews our bond with their internationally renowned team, and our connection with the thriving ‘Parkville Precinct’ medical research community. We look forward to identifying promising projects for collaboration, and jointly pursuing the potential to create transformational new therapies for patients.”

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the ONLY one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The exclusive leadership and influencer podcasts and vodcasts add huge value to our breaking news coverage. The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. Please click here to subscribe and visit T&Cs here.


News & Trends - Pharmaceuticals

Manoj Saxena - Bayer

Breaking the mold: Bayer GM on the future of pharma workplaces – Reimagining Healthcare Senior Leadership Series

Health Industry Hub | July 18, 2024 |

In the latest episode of the Reimagining Healthcare senior leadership series, Manoj Saxena, General Manager Pharmaceuticals ANZ at Bayer voiced […]

More


News & Trends - Pharmaceuticals

Matt Zeller, Country President of Novartis ANZ

Novartis Country President talks essentials in shaping the future of health policy: Reimagining Healthcare senior leadership series

Health Industry Hub | July 18, 2024 |

In this episode of the Reimagining Healthcare senior leadership series, Matt Zeller, Country President of Novartis ANZ, explores how health […]

More


Medical

First guidelines to stamp out rising scientific integrity issues in medical journals

First guidelines to stamp out rising scientific integrity issues in medical journals

Health Industry Hub | July 18, 2024 |

The number of retractions issued for scientific research articles in 2023 exceeded 10,000 – smashing annual records. To date, publishers […]

More


News & Trends - Pharmaceuticals

Gilead secures MSAC nod for CAR-T therapy

Gilead secures MSAC nod for CAR-T therapy

Health Industry Hub | July 18, 2024 |

Pharma News: Gilead Sciences welcomes the Medical Services Advisory Committee (MSAC) recommendation for public funding of Yescarta (axicabtagene ciloleucel) as […]

More


This content is copyright protected. Please subscribe to gain access.